Dimensional Fund Advisors LP Cuts Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

Dimensional Fund Advisors LP cut its holdings in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) by 8.4% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 56,548 shares of the company’s stock after selling 5,180 shares during the period. Dimensional Fund Advisors LP owned about 0.09% of Acumen Pharmaceuticals worth $137,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ABOS. Chicago Partners Investment Group LLC raised its holdings in shares of Acumen Pharmaceuticals by 34.9% during the fourth quarter. Chicago Partners Investment Group LLC now owns 18,315 shares of the company’s stock valued at $70,000 after buying an additional 4,736 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Acumen Pharmaceuticals during the first quarter worth approximately $52,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Acumen Pharmaceuticals in the first quarter valued at approximately $253,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Acumen Pharmaceuticals in the first quarter valued at approximately $4,449,000. Finally, Gladius Capital Management LP acquired a new stake in Acumen Pharmaceuticals during the 2nd quarter worth $26,000. 71.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Citigroup raised shares of Acumen Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Acumen Pharmaceuticals in a research report on Thursday, October 3rd. Finally, UBS Group cut their price objective on shares of Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th.

Acumen Pharmaceuticals Stock Down 0.9 %

Shares of ABOS stock opened at $2.33 on Wednesday. The company has a current ratio of 17.37, a quick ratio of 17.37 and a debt-to-equity ratio of 0.12. Acumen Pharmaceuticals, Inc. has a 1 year low of $1.81 and a 1 year high of $5.09. The firm’s fifty day moving average price is $2.54 and its two-hundred day moving average price is $2.89. The firm has a market capitalization of $139.99 million, a P/E ratio of -2.20 and a beta of 0.07.

Acumen Pharmaceuticals (NASDAQ:ABOS) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.06). During the same quarter last year, the business posted ($0.28) EPS. On average, equities analysts predict that Acumen Pharmaceuticals, Inc. will post -1.32 EPS for the current fiscal year.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.